AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Prostate Cancer|Advanced Solid Tumors
Interventions: DRUG: AZD5363|DRUG: Enzalutamide|DRUG: Fulvestrant
Sponsor: Memorial Sloan Kettering Cancer Center